Medtronic stock has delivered a decline of 26.0% over the past five years, yet its current checks point to a picture that is broadly in line with the intrinsic value estimate from a Discounted Cash Flow (DCF) model and an earnings multiple that screens as undervalued.

• Over a 5 year window, Medtronic has fallen 26.0%, which puts more focus on whether the current price reflects a reset in expectations rather than clear upside.
• Recent moves, including the SPR Therapeutics acquisition and involvement in stroke treatment technology, can support growth in pain and neuro-related therapies. However, any shortfall in cash flow from these efforts may weigh on what investors are willing to pay for the stock.
• Across the broader checks Medtronic scores 4 out of 6 on valuation, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Medtronic's current share price around US$82.35 already fairly reflects its intrinsic value and earnings potential, or if there is room for a valuation re rating from here.

Is Medtronic Fairly Priced on Cash Flow?

The Discounted Cash Flow (DCF) approach values Medtronic by projecting the cash it can return to shareholders over time and discounting that back to today. On this model, Medtronic is treated as a mature business with growing free cash flow rather than one relying on aggressive expansion assumptions.

The latest twelve month free cash flow sits at about $5.4b, and the 2 Stage Free Cash Flow to Equity model applies moderate growth expectations to arrive at an intrinsic value of roughly $88 per share. Set against the current share price around $82, that suggests the stock screens about 6.7% undervalued on the DCF output. Because the SPR Therapeutics acquisition brings additional non opioid pain treatments into Medtronic’s portfolio, the deal may help explain why the market is still willing to price in steady cash generation.

Overall, the Discounted Cash Flow work suggests Medtronic stock appears roughly fairly valued, with only a modest gap between price and intrinsic value.

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Is Medtronic a Bargain on Earnings?

The P/E ratio fits Medtronic because earnings remain a central reference point for investors in established medical equipment companies. On this measure, Medtronic trades at about 22.0x earnings, which is below both the Medical Equipment industry average of 26.9x and the peer group average of 31.4x.

The fair P/E ratio implied by the model is 29.6x, which is higher than where Medtronic currently trades. On this basis, the stock appears undervalued on earnings relative to what might be expected given its profile. That gap suggests the market is applying a discount despite the company’s role across devices, pain therapies and monitoring technology.

On the P/E yardstick, Medtronic stock appears undervalued compared with both industry norms and its own modelled fair multiple.

The Medtronic Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Medtronic pick up where the valuation work leaves off by spelling out which assumptions about Medtronic's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each Narrative ties a fair value to a clear storyline about Medtronic's potential catalysts and risks, so you can track over time which version of events appears to be unfolding on the Community page.

Medtronic draws sharply different views in the community, with one camp focused on product momentum and another on execution and margin risks.

Bull case: 16% undervalued

"Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends..."

Bear case: 6% overvalued

"The bearish analysts are assuming Medtronic's revenue will grow by 2.0% annually over the next 3 years..."

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

The Bottom Line

For Medtronic, the Discounted Cash Flow (DCF) work points to intrinsic value only modestly above the current share price, which suggests the stock is closer to fairly valued than a clear mispricing. The earnings multiple view is more generous, with Medtronic looking undervalued relative to peers on P/E, even after broader checks that lean mixed rather than emphatic. The key question from here is whether Medtronic can execute on its pipeline and margin plans well enough to close that gap between a cautious market rating and what the earnings based models imply, without cash flow slipping below expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.